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Background: Lymph nodes’ examination in colorectal cancer (CRC) resection specimens is an important determinant
that aids in the accuracy of CRC staging and treatment outcomes. Current guidelines call for the examination of at
least 12 lymph nodes (LN) in resected specimens in order to establish accurate staging.
Aim: To investigate lymph nodes’ examination protocol as it relates to accurate CRC staging.
Methods: We reviewed 216 African American CRC patients from 1996–2013 who underwent CRC resection and met
inclusion criteria for this study. The number of retrieved LNs, length of resected specimens, tumor grade, stage,
location, size and histology were examined.
Results: The cohort study was made of 49 % males, median age was 63 years and 45 % of patients were at stage III
and IV. The median (IQR) number of examined LNs was 15 (10–22) and the rate of patients with more than 12
examined LNs was 64 %. There was a gradual increase in the percentage of patients with adequate number (>12) of
examined LNs during the study period (from 60 % in 1996–2000 to 84 % in 2010–2013 period, P = 0.014). Adequate
LNs resection was neither associated with shift of stage from II to III (P = 0.3) nor with the changes from stage IIIa to IIIc
(P = 0.9). Metastatic LNs were observed in 8 % of samples with LNs (>12) vs. 13 % of samples with <12 examined LNs
(P = 0.1). Patients that had pre-surgical treatment (chemotherapy and radiotherapy) before surgery had <12 LNs
examined. There was also a trend of having more examined lymph nodes in large tumors.
Conclusions: Our study shows that there has been an increase in the number of lymph nodes examined in CRC
resections since the advent of the current quality initiative. However this increase does not seem to affect the stage or
percentage of metastatic lymph nodes’ detection in CRC patients.
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Colorectal cancer (CRC) is the third most common cancer
and the second most common cause of cancer related
deaths in both men and women in the United States
[1–3]. In 2013, it accounted for 102,480 new cases
and 50,090 deaths [4]. There are racial differences in CRC
incidence and mortality, when compared to other races,
African Americans (AAs) are disproportionately affected
and have a greater burden from this disease [5].* Correspondence: Hashktorab@howard.edu
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(http://creativecommons.org/publicdomain/zeIn 2011, AAs had the highest incidence of CRC (Male:
62.3/100,000 persons and Female: 47.5/100,000 persons)
when compared to Non-Hispanic Whites (Male: 49.6/
100,000 persons and Female: 37.3/100,000 persons) [6].
They also have poorer outcomes and are more likely to
die from CRC when compared to other races [3]. Several
studies have shown that AAs are more likely to be
diagnosed with advanced stage CRC and to have poorer
survival rates after diagnosis compared to whites [7–9].
One of the parameters used for CRC staging is the
evaluation of lymph nodes to determine if they are posi-
tive or negative for cancer. In patients with non-
metastatic CRC, lymph nodes’ status is the strongesticle is distributed under the terms of the Creative Commons Attribution 4.0
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studies have demonstrated increased survival in patients
who had a high number of lymph nodes evaluated [11].
Although this association cannot be fully explained, it is
thought to be due to the fact that patients who have
more extensive LNs’ evaluation are at lower risk of being
understaged. Understaged patients receive inadequate
treatment leading to lower survival rates [11].
Adequate evaluation of LNs is important for therapeutic
and prognostic reasons. Patients with positive LNs have to
undergo adjuvant post-surgery chemotherapy because of
the high risk of tumor recurrence [12]. This serves also to
determine the accuracy of staging in patients with CRC
[12]. The current standard of care recommended by the
1990 working party report to the World Congresses of
Gastroenterology and also by the 2002 American Joint
Committee on Cancer (AJCC) advocates for the
examination of at least 12 lymph nodes in patients
with CRC [13].
Our study aims to investigate the number of examined
lymph nodes, their associated features and the pathology
protocol used for their evaluation as these relate to proper
and accurate staging of CRC in African Americans
afflicted with this disease.
Methods
Patients
We reviewed the medical records of 216 African American
patients with a diagnosis of CRC from January 1, 1996 to
December 30, 2013. Data was retrieved from the database
of the Department of Pathology and the Tumor registry
unit of the Cancer Center at Howard University Hospital,
an inner city tertiary institution in Washington DC. The
Institutional Review Board at Howard University Ethics
Committee approved the research protocol (06-MED-39).
Due to the retrospective nature of the study no written in-
formed consent for participation in the study was needed
and no children were included in the study. The pathology
reports on the tumor and specimen features as well as the
examined and positive lymph nodes were investigated for
each patient by GI pathologists (E.L. and B. S.).
Pathological evaluation
Gastrointestinal Pathologists evaluated all specimens in
this study. Colectomy specimens were evaluated based
on grade, stage and other features. Foci of metastatic
adenocarcinoma were explored. The foci usually locate in
subcapsular specs and later involve parenchyma. During
the gross evaluation of each resected specimen, all grossly
negative or equivocal lymph nodes have been submitted
entirely for microscopic evaluation. The accuracy and pre-
dictive value of stage assignment are directly proportional
to the thoroughness of the surgical technique in removing
all regional nodes and the pathologic examination of theresection specimens in identifying and harvesting all
regional lymph nodes for microscopic assessment.
Statistical analysis
Distribution of categorical variables was assessed by
table of frequency and for continuous variables by
median (interquartile range). We tested the relationship
between the number of examined LNs (as a continuous
variable or as two categories of >12 vs. ≤ 12) and stage
by ANOVA or Chi-square.
Results
Clinicopathological features of the analyzed cohort
During the 17 years of review, we had a total of 216
CRC patients, 50 % of them were operated after 2007
(Table 1). The median age was 63 years old (interquartile
range = 53-72) and 49 % (n = 106) of the study population
was male. Ninety seven percent of tumors were adenocar-
cinoma and most were low grade tumors (95 %, n = 184).
Most tumors were located at the ascending colon (41 %,
n = 86) and rectosigmoid (37 %, n = 77).
CRC stage distribution and lymph nodes’ examination
Thirty four percent of patients had stage II tumors
[IIa(20 %), IIb(14 %)], 35 % had stage III [IIIa (2 %), IIIb
(20 %), IIIc (13 %)], 9 % had stage IV disease[Iva (8 %),
IVb (1 %)]. The median (IQR) number of examined LNs
was 15 (10–22) and the rate of patients with more than
12 resected LNs was 64 %. Among patients with stage II,
the frequency of adequate LNs resection was 59 % vs.
67 % in patients with stage III (P = 0.3). These frequen-
cies at stage IIIa, IIIb and IIIc were 80 %, 76 % and 54 %,
respectively (P = 0.1; Fig. 1). Metastatic LNs were
observed in 8 % of samples with adequate number of
examined LNs and in 13 % with less than 12 examined
LNs (P = 0.1).
The median number of examined LNs in patients with
stage I and II was 15 and 14, respectively. In patients
with stage IIIa, the median number of examined LNs
was 19, decreasing to 15 in patients with stage IIIb and
14 in patients with stage IIIc (P for trend = 0.2). The
median number of lymph nodes in patients with stage
IV was 17.
Lymph nodes’ examination and other clinicopathological
characteristics
Patients with inadequate number of examined lymph
nodes were older (median age of 68 yrs vs. 61 yrs,
P = 0.002). The frequency of adequate LN in 120 patients
over 60 was 59 % (vs. 71 % in 92 patients <61 years
old, P = 0.08). The proportion of metastatic lymph node
was not different between age groups (P = 0.3). Presurgical
radiotherapy and chemotherapy were more frequent in
this group of patients (P = 0.05). Gender, tumor location
Table 1 Distribution of demographic, clinical and pathologic
CRC variables
Number Results
Age, median (Interquartile range) 214 63 (53–72)
Male, no (%) 216 106 (49)
Location 210
Ascending 86 (41 %)
Transverse 21 (10 %)
Descending 26 (12 %)
Rectosigmoid 77 (37 %)
Histology 215
Adenocarcinoma 179 (83 %)
Mucinous Adenocarcinoma 31 (14 %)
Other 5 (3 %)
Chemotherapy before surgery, no (%) 216 11 (5 %)
Radiotherapy before surgery, no (%) 216 11 (5 %)
Grade 193
Low 184 (95 %)
High 10 (5 %)
Stage, no (%) 209
I 46 (22 %)
II 71 (34 %)
III 74 (35 %)
IV 18 (9 %)
Number of LN resected 214
≤12 77 (36 %)
>12 137 (64 %)
Median (interquartile) 15 (10–22)
Tumor size, Median (interquartile) cm 192 4.5 (3.0-5.7)
Specimen size, Median (interquartile) cm 188 33 (21–61)
Number of metastatic LNs, Median (interquartile) 214 0 (0–2)
Ratio of metastatic LNs to total LNs examined,
Median (interquartile)
214 0 (0–0.09)
*Some of the data is missing
n = 216*
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different between these two groups. There was a
gradual increase in the percentage of patients with
adequate number (>12) of examined LNs during the
study period (from 60 % in 1996–2000 to 84 % in
2010–2013 period, P = 0.014). The number of meta-
static lymph nodes and also the ratio of metastatic to
total lymph nodes were not different between the two
groups (Table 2). Also, the number or ratio of meta-
static lymph nodes were not correlated to tumor size
(P = 0.1).The frequency of adequate lymph nodes or
stage were not significantly different between patholo-
gists. There was a significant correlation betweentumor extent (T) and number of metastatic lymph
nodes (r = 0.28, P = 0.0001).
Subgroup analysis of patients with less than 12 lymph
node examined
Sixty seven (31 %) patients had less than 12 LNs
examined. In this subgroup of patients there was no
correlation between the number of examined LNs and
that of metastatic ones (r = 0.18, P = 0.1). There was
also no correlation with stage (r = 0.2, P = 0.2). Also in this
subgroup, increasing the number of examined lymph
nodes did not shift the stage from II to III (P = 0.6).
Discussion
Adequate examination of lymph nodes is important in
patients with CRC; because lymph nodes’ status is a
strong predictor of long term outcome in CRC patients
[10]. Current guidelines recommend that at least 12 LNs
should be harvested and examined in patients with CRC
[14]. In this study among African American patients
with CRC, we shows there has been an increase in the
number of lymph nodes examined in colon cancer resec-
tion specimens since the advent of the current quality
initiatives. The increase however does not lead to stage
migration in our cohort of patients or to an increase in
the percentage of metastatic lymph nodes.
The number of examined lymph nodes after colectomy
is important for accurate staging and treatment design
and also serves as a quality care indicator at the hospital
level [15, 16]. Various factors influence the number of
LNs retrieved including tumor’s size and stage [10],
patient’s age and gender [17], surgeon and surgical
procedure [18], pathologist [18] and presurgical chemo-
therapy/radiotherapy [19, 20]. Studies have shown that
ethnic minorities are consistently underrepresented and
underreported in medical research studies [21]. Cone
et al. explored the relationship between lymph nodes’
count and ethnicity and indicated ethnicity as an import-
ant variable when assessing lymph nodes’ count with
Hispanics having a lower chance of having ≥12 LNs
evaluated when compared to Caucasians [18]. There are
however no studies showing this relationship in African
Americans. Our study was conducted in an African
American urban patient population to address this gap
of knowledge.
Our study showed that the majority (64 %) of patients
in our cohort had more than 12 LNs examined with a
median number of 15 LNs (range: 10–22). Also 84 % of
CRC sample in recent years (2010–2013) had more than
12 LNs. This number exceeds the recommended bench-
mark of 12 LNs and is in compliance with the national
guidelines. This result is not consistent with previous
studies where the median number of examined LNs was
less than 12 [10]. Our results are also not consistent
Fig. 1 Percentage of adequate LNs examined at different stages of CRC in in African Americans. For stages IIIa, IIIb and IIIc, these percentages
were 80 %, 76 % and 54 %, respectively
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are likely to undergo inadequate lymph nodes’ examin-
ation [22]. Our findings reflect that our procedure for
the retrieval and examination of LNs are very aggressive
and are way above the current gold standard. Of the
36 % of patients in our study with less than 12 examined
LNs, 12 % had no further need for LNs’ examination
since positive LNs for staging were already detected
while in the remaining 24 % of patients with less than 12Table 2 Clinical and pathologic characteristics of CRC by






Age, median (Interquartile range) 68 (56–77) 61 (62–69) 0.002
Male, no (%) 42 (55) 63 (46) 0.2
Location 0.3
Ascending 28 (37 %) 56 (42 %)
Transverse 9 (12 %) 12 (9 %)
Descending 6 (8 %) 20 (15 %)
Rectosigmoid 32 (43 %) 45 (34 %)
Chemotherapy before surgery, no (%) 7 (9 %) 4 (3 %) 0.05
Radiotherapy before surgery, no (%) 7 (9 %) 4 (3 %) 0.05
Tumor largest size, Median
(interquartile) cm
4.0 (3.0-5.5) 4.5 (3.0-5.7) 0.4
Specimen largest size, Median
(interquartile) cm
31 (18–67) 33 (23–60) 0.9
Number of metastatic LNs,
Median (interquartile)
0 (0–1) 0 (0–2) 0.1
Ratio of metastatic LNs to total LN
examined, Median (interquartile)
0 (0–0.14) 0 (0–0.09) 0.6examined LNs, no further LNs could be retrieved from
the colectomy specimens.
In 2007, the National Quality Forum listed the presence
of at least 12 lymph nodes in a surgical resection specimen
among the key quality measures for colon cancer care in
the United States [14]. Increasingly, however, evidence
indicates that this bar should be raised, as the greater the
number of examined LNs, the greater the likelihood of
detection of metastasis, suggesting that no minimum
number of LNs accurately or reliably stages all patients
[23, 24]. Indeed, in a recent case, we examined 33 LNs to
find only one positive after reviewing the first 24 LNs. In
this case, checking just 12 or even 24 LNs would have re-
sulted in missing a positive LN and affected the treatment
regimen plan for this patient.
More importantly, it has been shown that clinical
outcome is linked to lymph nodes retrieval in stage II
disease. Numerous studies have shown that conven-
tional pathologic examination of increased numbers
of lymph nodes is itself associated with an increased
survival advantage in stage II disease [15], indicating
a positive effect of optimal mesenteric resection by
the surgeon and optimal LNs retrieval and examin-
ation from the resection specimen by the pathologist.
As previously mentioned the number of lymph nodes
recovered from resection specimen is dependent on
several factors. Surgical technique, surgery volume, and
patient factors (like age, size of tumor, size of specimen,
administration of neoadjuvant therapy and anatomic
variation) alter the actual number of nodes in a resection
specimen, but the diligence and skill of the pathologist
in identifying and harvesting lymph nodes in the resec-
tion specimen are also major factors. Lymph nodes may
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patients [25] and after neoadjuvant therapy [26] . In our
study 56 % (n = 120) of our patients were elderly with
59 % having adequate number of LNs examined (vs.
71 % in 92 patients <61 years old, P = 0.08). This is
consistent with other studies that report a negative
correlation between lymph node yield and increasing age
[27]. Because it has been shown that nodal metastasis in
colorectal cancer is often found in small lymph nodes
(<5 mm in diameter), diligent search for lymph nodes is
required on gross examination of resection specimens.
Patients with stage III or IV colorectal cancer may
receive presurgical chemotherapy and radiotherapy to
reduce the number of metastatic LNs and to shrink the
size of the tumor. In our study 11 (5 %) of our patients
had presurgical treatment with the majority (n = 7)
having less than 12 LNs examined (Table 2). This is con-
sistent with other studies that showed reduced LNs yield
in patients that received presurgical treatment [25, 26].
Another important factor is the size of tumor and size of
specimen, increased specimen/tumor size positively
correlated with higher number of LNs available in colec-
tomy specimens, this difference was however not statisti-
cally significant in our cohort.
The decision to create the current guidelines was
based on the assumption that the examination and
analysis of more lymph nodes in patients with CRC will
help prevent the omission of positive lymph nodes [27].
Based on the current American Joint Committee on
Cancer (AJCC) TNM staging system, discovery of posi-
tive lymph nodes results in a shift in stage from stage I
or II disease to stage III or IV. However, our study shows
that increased examination and adequate lymph node
retrieval was not associated with a shift in stage from
stage II to III (P = 0.3). It was also not associated with a
change in stage from stage IIIa to IIIb or IIIc. This is
consistent with other studies showing that increased
examination of lymph nodes is not associated with
increase in node positive patients [11, 28, 29].
There was an increase in the percentage of patients
who had more than 12 LNs examined as we upstage.
Baxter et al. report tumor factors as important determi-
nants of lymph nodes retrieval [10]. They also observed
that more lymph nodes are examined in patients with
stage II and III compared to patients with stage I [10].
This is consistent with our study in which there was a
marked increase in the percentage of patients that had
more than 12 LNs examined as we upstage. It was
particularly noticeable in patients with stage IIIa and up.
Also in patients with stage III disease, there was a steady
decline in the number of examined LNs as we upstage
from IIIa to IIIb and then IIIc. This may be attributed to
the fact that in patients with stage III, positive LNs are
important for staging and once the required numbers ofpositive nodes are detected, the pathologists may not
aggressively look for other lymph nodes (p = 0.11,
stage 3 p = 0.058).
Our study has some limitations. It is a retrospective
study; it is therefore limited by differences in data input
over time and not having the chance to review the cases
again, and adherence with previous guideline. It is also a
single institutional study with a relatively small sample
size. We are going to eliminate this limitation in our
prospective future study.
Conclusion
Our study shows there has been an increase in the number
of lymph nodes (>12) examined in colon cancer resection
specimens since the advent of the current quality ini-
tiatives. The increase however does not lead to stage
migration in our cohort of patients or to an increase in
the percentage of metastatic lymph nodes. Metastatic LNs
were observed in less of samples with LNs (>12) than
samples with <12 LNs. There was also a trend of having
more examined lymph nodes in large tumors.
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